ERSPC and PLCO Prostate Cancer Screening Studies: What Are the Differences?

European Urology

Volumn 58, Issue 1, 2010, Pages 46-52

  Schröder, Fritz H ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; BLOOD SAMPLING; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; ECHOGRAPHY; EDITORIAL; EUROPE; FOLLOW UP; GLEASON SCORE; HEALTH CARE SYSTEM; HUMAN; INFORMATION PROCESSING; INFORMED CONSENT; MALE; MEDICAL DECISION MAKING; METHODOLOGY; PATIENT SELECTION; PILOT STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE;

AGED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77952862416     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.03.033     Document Type: Editorial

References (21)

1. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320-1328
2. Andriole G.L., Crawford E.D., Grubb III R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360 (2009) 1310-1319
3. Barry M.J. Screening for prostate cancer-the controversy that refuses to die. N Engl J Med 360 (2009) 1351-1354
4. Roobol M.J., and Schröder F.H. The European Randomized Study of Screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results 1994-2003. BJU Int 92 Suppl 2 (2003) 1-122
5. Gohagan J.K., Prorok P.C., Kramer B.S., and Cornett J.E. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol 152 (1994) 1905-1909
6. Prorok P.C., Andriole G.L., Bresalier R.S., et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 21 Suppl 6 (2000) 273S-309S
7. Gohagan J.K., Prorok P.C., Hayes R.B., and Kramer B.S. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 21 Suppl 6 (2000) 251S-272S
8. Schröder F.H., Denis L.J., Kirkels W., de Koning H.J., and Standaert B. European Randomized Study of Screening for Prostate Cancer. Progress report of Antwerp and Rotterdam pilot studies. Cancer 76 (1995) 129-134
9. Schröder F.H., Damhuis R.A.M., Kirkels W.J., et al. European Randomized Study of Screening for Prostate Cancer-the Rotterdam pilot studies. Int J Cancer 65 (1996) 145-151
10. Schröder F.H., Denis L.J., Roobol M.J., et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 92 Suppl 2 (2003) 1-13
11. de Koning H.J., Liem M.K., Baan C.A., Boer R., Schröder F.H., and Alexander F.E. ERSPC. Prostate cancer mortality reduction by screening: power and time frame with complete enrolment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 98 (2002) 268-273
12. de Koning H.J., Hakulinen T., Moss S.M., Adolfsson J., Smith P.H., and Alexander F.E. ERSPC. Monitoring the ERSPC trial. BJU Int 92 Suppl 2 (2003) 112-114
13. Ciatto S., Zappa M., Villers A., Paez A., Otto S.J., and Auvinen A. Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU Int 92 Suppl 2 (2003) 97-100
14. Schröder F.H., van der Maas P., Beemsterboer P., et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst 90 (1998) 1817-1823
15. Schröder F.H., Roobol-Bouts M., Vis A.N., van der Kwast T., and Kranse R. Prostate-specific antigen-based early detection of prostate cancer-validation of screening without rectal examination. Urology 57 (2001) 83-90
16. Wolters T., Roobol M.J., Steyerberg E.W., et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer 126 (2009) 2387-2393
17. Grubb III R.L., Pinsky P.F., Greenlee R.T., et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 102 (2008) 1524-1530
18. Roobol M.J., Kerkhof M., Schröder F.H., et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 56 (2009) 584-591
19. Cuzick J., Edwards R., and Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 16 (1997) 1017-1029
20. Dubben H.H. Trials of prostate-cancer screening are not worthwhile. Lancet Oncol 10 (2009) 294-298
21. Roobol M.J., Steyerberg E.W., Kranse R., et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 57 (2010) 79-85